Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Senate Finance Dems Back Public Plan, Blue Dogs Back Away
Sen. Max Baucus, D-Mont., chairman of the Finance Committee expects the Senate"s health care overhaul proposal to include a public health insurance plan, Dow Jones Newswire reports, adding that Baucus was "following the lead of President Obama and drawing a line in the sand on the controversial issue." The President strongly supported the public option in a letter to senators Wednesday.
generic viagra online
New Biological Therapy Ilaris(R) Approved In US To Treat Children And Adults With CAPS, A Serious Life-Long Auto-Inflammatory Disease
The U.S. Food and Drug Administration (FDA) has approved Ilaris(R) (canakinumab) for the treatment of children and adults with cryopyrin-associated periodic syndrome (CAPS), which includes a number of rare, but life-long, auto-inflammatory disorders with debilitating symptoms and limited treatment options. The FDA granted priority review to Ilaris based on its potential to meet an important clinical need for patients with CAPS.
News of the day
Echo-Location In Humans Developed By Spanish Scientists
A team of researchers from the University of Alcalá de Henares (UAH) has shown scientifically that human beings can develop echolocation, the system of acoustic signals used by dolphins and bats to explore their surroundings. Producing certain kinds of tongue clicks helps people to identify objects around them without needing to see them, something which would be especially useful for the blind.
Endocrinology

FDA Reviewing Preliminary Safety Information On Asthma Drug Xolair

The U.S. Food and Drug Administration announced that it is conducting a safety review of Xolair (omalizumab), a drug used to treat certain adults and adolescents with moderate-to-severe persistent asthma. Reviewers are looking for a possible association between patients who use Xolair and an increased risk of heart attack, abnormal heart rhythm, heart failure, and stroke. The possible association has been identified based on interim results from an ongoing study of Xolair known as Evaluating the Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS). The study is being conducted by the manufacturer, San Francisco-based Genentech Inc. An FDA Early Communication is available online. The Early Communication is in keeping with the FDA"s commitment to inform the public about its ongoing safety reviews of drugs. Once its review is completed, the FDA will communicate its findings and any resulting recommendations to the public. Until the evaluation is completed, health care professionals and patients should be aware that the agency is reviewing data that may suggest a risk of adverse events. The FDA is not advising a change in prescribing or use of the drug. U.S. Food and Drug Administration


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009